Related content

Neutralizing antibodies in interferon beta treated patients with multiple sclerosis: knowing what to do now: Commentary to: 10.1007/s00415-010-5844-5 “One-year evaluation of factors affecting the biological activity of interferon beta in multiple sclerosis patients” by S. Malucchi et al.

By Menge Til   Hartung Hans-Peter   Kieseier Bernd  

Journal of Neurology, Vol. 258, Iss. 5, 2011-05 ,pp. : 904-907

Springer Publishing Company

Access to resources Recommend Favorite

Interferon beta treatment: Bioavailability and antiviral activity in multiple sclerosis patients

By Garcia-Montojo Marta   Heras Virginia De Las   Bartolome Manuel   Arroyo Rafael   Alvarez-Lafuente Roberto  

Journal of NeuroVirology, Vol. 13, Iss. 6, 2007-11 ,pp. : 504-512

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Beta-interferon and multiple sclerosis

By Hall G.L.   Compston A.   Scolding N.J.  

Trends in Neurosciences, Vol. 20, Iss. 2, 1997-02 ,pp. : 63-67

Elsevier

Access to resources Recommend Favorite

Pharmacodynamics of interferon beta in multiple sclerosis patients with or without serum neutralizing antibodies

By Scagnolari Carolina   Duda Petra   Bagnato Francesca   Vito Gabriella   Alberelli Alessia   Lavolpe Vito   Girardi Enrico   Durastanti Valentina   Trojano Maria   Kappos Ludwig   Antonelli Guido  

Journal of Neurology, Vol. 254, Iss. 5, 2007-05 ,pp. : 597-604

Springer Publishing Company

Access to resources Recommend Favorite

Interferon-beta or azathioprine as add-on therapies in patients with active multiple sclerosis

By Ticha Veronika   Kalincik Tomas   Havrdova Eva  

Neurological Research, Vol. 34, Iss. 10, 2012-12 ,pp. : 923-930

Maney Publishing

Access to resources Recommend Favorite